Title: Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk
analysis on metabolic disorders
Version: 2 Date: 09 Apr 2025
Reviewer:  Giuseppe Guido Maria Scarlata
Reviewer's report:
In the present paper the Authors suggests that MAFLD is a more effective indicator for
identifying patients at increased risk for metabolic disorders. The paper il clear and well written.
However, i have some suggestions to improve it:
1. Underline the crucial role of the gut microbiota in the pathogenesis of fatty liver disease (see
10.20517/2394-5079.2023.134 );
2. Please, compare your study with other studies in the current literature. Moreover, consider
to address the key findings and the main criticisms of the different applications of these new
nomenclatures in the clinical context;
3. The methodological part was conducted with regards to ultrasound evaluation. However, the
transient elastography use deserves more attention;
4. I suggest to write an abbreviation list to facilitate the readers.
Title: Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk
analysis on metabolic disorders
Version: 2 Date: 09 Apr 2025
Reviewer:  Giuseppe Guido Maria Scarlata
Reviewer's report:
In the present paper the Authors suggests that MAFLD is a more effective indicator for
identifying patients at increased risk for metabolic disorders. The paper il clear and well written.
However, i have some suggestions to improve it:
1. Underline the crucial role of the gut microbiota in the pathogenesis of fatty liver disease (see
10.20517/2394-5079.2023.134 );
2. Please, compare your study with other studies in the current literature. Moreover, consider
to address the key findings and the main criticisms of the different applications of these new
nomenclatures in the clinical context;
3. The methodological part was conducted with regards to ultrasound evaluation. However, the
transient elastography use deserves more attention;
4. I suggest to write an abbreviation list to facilitate the readers.
Please review this paper.
user
Title: Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk
analysis on metabolic disorders
Version: 2 Date: 09 Apr 2025
Reviewer:  Giuseppe Guido Maria Scarlata
Reviewer's report:
In the present paper the Authors suggests that MAFLD is a more effective indicator for
identifying patients at increased risk for metabolic disorders. The paper il clear and well written.
However, i have some suggestions to improve it:
1. Underline the crucial role of the gut microbiota in the pathogenesis of fatty liver disease (see
10.20517/2394-5079.2023.134 );
2. Please, compare your study with other studies in the current literature. Moreover, consider
to address the key findings and the main criticisms of the different applications of these new
nomenclatures in the clinical context;
3. The methodological part was conducted with regards to ultrasound evaluation. However, the
transient elastography use deserves more attention;
4. I suggest to write an abbreviation list to facilitate the readers.
assistant